Skip to main content

parp1 inhibitor hrs-1167

Generic: PARP1 Inhibitor HRS-1167

parp1 inhibitor hrs-1167: 2 clinical trials tracked.

parp1 inhibitor hrs-1167 evidence translation

What we can confirm

2 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about parp1 inhibitor hrs-1167, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 0 study sponsors

Related indications

Advanced Solid Tumor

Study sponsors

No additional listed-company sponsor is linked.

Clinical Trial Registry Records (2)

An Open Label, Multicenter, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of the PARP1 Inhibitor M9466 in Combination With Topoisomerase 1 Inhibitor-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)

NCT06509906Registry updated 2025-12-18·Phase 1
Terminated

Primary endpoint: Number of Participants with Treatment-Emergent Adverse Events (TEAEs) and Treatment Related TEAEs

Interventionalopen3 targetStarted 2024-10Completion 2025-1212 sites · Australia, Japan, South Korea, Spain…EMD Serono Research & Development Institute, Inc.

An Open Label, Multicenter, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of the PARP1 Inhibitor M9466 Alone or in Combination in Participants With Advanced Solid Tumors

NCT06421935Registry updated 2026-09-09·Phase 1
Active, not recruiting

Primary endpoint: Module 1 Part A1 and Part A2: Number of Participants With Treatment-Emergent Adverse Events (TEAE), and Treatment-related AEs (TRAEs)

InterventionalRandomizedopen60 enrolledStarted 2024-08Completion 2027-0220 sites · Australia, Japan, South Korea, Spain…EMD Serono Research & Development Institute, Inc.